Literature DB >> 22286034

A new strategy for metabolic stabilization of motilin using the C-terminal part of ghrelin.

Naomi Morozumi1, Seiji Sato, Sayaka Yoshida, Akira Yamaki, Mayumi Furuya, Norio Inomata, Norio Ohnuma, Yoshiharu Minamitake, Kazuhiro Ohsuye, Kenji Kangawa.   

Abstract

Ghrelin consists of 28 amino acid residues with an octanoyl modification at the third serine residue. Recently we have found that the C-terminal part of ghrelin protects the ester bond of 3-octanoyled serine from plasma esterases and plays the essential role to prolong the plasma half-life and to show its biological activity in vivo. In the present study, we researched whether the C-terminal part of ghrelin has a potential to prolong the plasma half-life of motilin, by comparing the pharmacokinetics of various chimeric peptides of ghrelin and motilin. Motilin is another gastro-intestinal peptide hormone related with ghrelin structurally, binding to the same family of G protein-coupled receptors. Chimeric peptides were designed to be composed of motilin(1-12) fragment, the active core binding to the motilin receptor, GPR38, and C-terminal part of ghrelin. The modification of motilin(1-12) fragment by C-terminal part of ghrelin hardly influenced its agonist activity to GPR38 and almost all these chimeric peptides showed more than two times longer plasma half-lives than motilin in rats. From the relationship between structures of chimeric peptides and their corresponding plasma half-lives, the mid-region of ghrelin rich in basic amino acids ((15)RKESKK(20)) was considered to be the most important in prolonging the plasma half-life of motilin. The deletion of these fragments or replacement of 17th glutamic acid with a neutral amino acid resulted in short plasma half-lives. In conclusion, our data suggested that the C-terminal part of ghrelin has a potential to improve the biokinetics of motilin probably by a metabolic stabilizing effect.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286034     DOI: 10.1016/j.peptides.2012.01.010

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism.

Authors:  Naomi Morozumi; Takafumi Yotsumoto; Akira Yamaki; Kazunori Yoshikiyo; Sayaka Yoshida; Ryuichi Nakamura; Toshimasa Jindo; Mayumi Furuya; Hiroaki Maeda; Yoshiharu Minamitake; Kenji Kangawa
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

2.  Multi-species sequence comparison reveals conservation of ghrelin gene-derived splice variants encoding a truncated ghrelin peptide.

Authors:  Inge Seim; Penny L Jeffery; Patrick B Thomas; Carina M Walpole; Michelle Maugham; Jenny N T Fung; Pei-Yi Yap; Angela J O'Keeffe; John Lai; Eliza J Whiteside; Adrian C Herington; Lisa K Chopin
Journal:  Endocrine       Date:  2016-01-20       Impact factor: 3.633

3.  Safety assessment of a novel C-type natriuretic peptide derivative and the mechanism of bone- and cartilage-specific toxicity.

Authors:  Takafumi Yotsumoto; Naomi Morozumi; Ryuichi Nakamura; Toshimasa Jindo; Mayumi Furuya; Yasuyuki Abe; Tomonari Nishimura; Hiroaki Maeda; Hiroyuki Ogasawara; Yoshiharu Minamitake; Kenji Kangawa
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.